Quick Answer
Tyra Biosciences, Inc. reported Cash and Equivalents of $77.39 million for fiscal year 2025.
Tyra Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $77.39M | -15.9% |
| 2024 | $91.97M | +58.5% |
| 2023 | $58.01M | -76.9% |
| 2022 | $251.21M | -16.9% |
| 2021 | $302.18M | +1884.9% |
| 2020 | $15.22M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $61.95M | -40.4% | -37.1% |
| June 30, 2025 | $98.49M | -1.0% | -2.2% |
| March 31, 2025 | $100.72M | -60.4% | +9.5% |
| December 31, 2024 | $91.97M | +58.5% | -11.5% |
| September 30, 2024 | $103.89M | -51.8% | +4.4% |
| June 30, 2024 | $99.49M | -57.2% | -60.9% |
| March 31, 2024 | $254.37M | +5.2% | +338.5% |
| December 31, 2023 | $58.01M | -76.9% | -73.1% |
- Tyra Biosciences, Inc. showed a decrease of -15.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Tyra Biosciences, Inc.’s cash and equivalents has grown by 408.3% (from $15.22 million to $77.39 million).
- The most recent figure is from Tyra Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: